GRS Home

The Growth Hormone Research Society

Pituitary

NEXT MEETING  


The 11th International Congress of the Growth Hormone Research Society is organized in collaboration with the European Society of Endocrinology during the days preceding ECE2026 (pre-congress event).

Date and time
Friday 8 - Saturday 9 May 2026. This event will start at 09:00 on Friday and will finish in time for delegates to attend the ECE 2026 Opening Ceremony on Saturday.

Location
ECE 2026 venues - Prague Congress Centre, Room TBC

Program
The meeting will provide an update on basic, translational and clinical research in the field of growth hormone related diseases. The format includes plenaries from leading experts in the field, and abstract based oral and poster sessions. The program can be found here:11th International Congress of the Growth Hormone Research Society (GRS)

Submission of Abstracts
Abstracts for this Congress must be submitted by email directly to the Growth Hormone Research Society: grs@clin.au.dk. Guidelines for preparation and submission of abstracts can be found here. Abstract submission deadline for the GRS congress is Friday 17 April 2026. Notification to authors of abstract acceptance/rejection – end of April 2026.

Delegate fee (GRS congress only)
In-person = 100 Euro In-person (in-training, nurse, Early Career) = 50 Euro NB - there is not an option to attend this congress online. The registration fees shown here do not include registration for ECE2026.

Registration details
You must register for this event through your ECE 2026 registration (you do not have to attend ECE 2026, but your registration will only be valid for the Pre-Congress Course). Follow this link to register.

Contact
For further information, please contact the ECE 2026 Congress team at ece2026-congress@interplan.de or send an email to GRS at grs@clin.au.dk

Travel grants
Travel grants are available from GRS for early career attendees who present an abstract. Follow this link for details.



For ECE2026 information visit: ECE 2026



Human Growth Homone Indications


FDA approved uses of GH according to the DEA and updated in Aug 2009

http://www.deadiversion.usdoj.gov/drugs_concern/hgh.htm

In children hGH is approved for the treatment of poor growth due to Turner’s syndrome, Prader-Willi syndrome, and chronic renal insufficiency, hGH insufficiency/deficiency, for children born small for gestational age, and for idiopathic short stature. Accepted medical uses in adults include but are not limited to the treatment of the wasting syndrome of HIV/AIDS and hGH deficiency.

Updated Guidelines for GH Therapy 2003

In August 1996, the FDA approved GH for use in adult patients with GHD. The only approved indication was pituitary disease from known causes, including pituitary tumor, pituitary surgical damage, hypothalamic disease, irradiation, trauma, and reconfirmed childhood GHD. Most patients considered for GH therapy are in one of these categories. A few patients with definite GHD, however, have other kinds of pituitary-hypothalamic disease; these include patients with Sheehan’s syndrome, autoimmune hypophysitis, or hypophysitis associated with other inflammatory conditions, such as sarcoidosis..."

The US FDA has approved GH for use in the following pediatric conditions:
• Growth hormone deficiency
• Turner syndrome
• Chronic renal insufficiency
• Small for gestational age or intrauterine growth retardation
• Prader-Willi syndrome
• Continued height deficit at puberty."

New indications for GH 2005 has a table summarizing the use of growth hormone (GH) therapy in short stature both in the US and Europe:

Treatment recommended by NICE (National Institute for Clinical Excellence) guidelines 2002 in the UK
• GH deficiency, isolated or as part of multiple pituitary hormone deficiency
• Turner syndrome
• Prader Willi syndrome
• Short stature associated with chronic renal failure

Licensed indications in Europe
• GH deficiency, isolated or as part of multiple pituitary hormone deficiency
• Turner syndrome
• Prader Willi syndrome
• Short stature associated with chronic renal failure
• Short stature associated with low birth weight

Licensed in the USA, but not in Europe
• Idiopathic short stature
Short stature conditions where there have been trials of treatment with GH but outcome is not clear (not licensed indications)
• Noonan syndrome
• Skeletal dysplasia
• Rheumatoid arthritis
• Down syndrome
• Short stature associated with prolonged steroid use
• Aarskog’s syndrome

 

 

Constitution

 

Consensus Statements

 

Honorary Members

 

hGH Indications

 

Officers

IGF Society

Links